ACS Medicinal Chemistry Letters
Page 6 of 8
packaging signal. Implications for genome recognition. J. Mol. Biol.
2000, 301 (2), 491-511.
AUTHOR INFORMATION
Corresponding Author
1
2
3
4
5
6
7
8
13.
Bourbigot, S.; Ramalanjaona, N.; Boudier, C.; Salgado, G.
F.; Roques, B. P.; Mely, Y.; Bouaziz, S.; Morellet, N., How the HIV-
1 nucleocapsid protein binds and destabilises the (-)primer binding
site during reverse transcription. J. Mol. Biol. 2008, 383 (5), 1112-28.
* Maurizio Botta, Department of Biotechnology, Chemistry and
Pharmacy, “department of excellence 2018-2022”, University of
Siena, via Aldo Moro 2, 53100 Siena. Italy. Phone: Tel. +39 0577
234306. Fax. +39 0577 234303. E-mail: botta@unisi.it
14.
Beltz, H.; Clauss, C.; Piemont, E.; Ficheux, D.; Gorelick,
R. J.; Roques, B.; Gabus, C.; Darlix, J. L.; de Rocquigny, H.; Mely,
Y., Structural determinants of HIV-1 nucleocapsid protein for cTAR
DNA binding and destabilization, and correlation with inhibition of
self-primed DNA synthesis. J. Mol. Biol. 2005, 348 (5), 1113-26.
Author Contributions
All authors have given approval to the final version of the
manuscript.
9
15.
De Guzman, R. N.; Wu, Z. R.; Stalling, C. C.; Pappalardo,
L.; Borer, P. N.; Summers, M. F., Structure of the HIV-1
nucleocapsid protein bound to the SL3 psi-RNA recognition element.
Science 1998, 279 (5349), 384-8.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FUNDING SOURCES
This project has received funding from the European Union’s
Seventh Programme for research, technological development, and
demonstration under grant agreement no. 601969.
16.
Didierlaurent, L.; Houzet, L.; Morichaud, Z.; Darlix, J. L.;
Mougel, M., The conserved N-terminal basic residues and zinc-finger
motifs of HIV-1 nucleocapsid restrict the viral cDNA synthesis during
virus formation and maturation. Nucleic Acids Res. 2008, 36 (14),
4745-53.
REFERENCES
1.
Mori, M.; Kovalenko, L.; Lyonnais, S.; Antaki, D.; Torbett,
17.
Berthoux, L.; Pechoux, C.; Ottmann, M.; Morel, G.; Darlix,
B. E.; Botta, M.; Mirambeau, G.; Mely, Y., Nucleocapsid Protein: A
Desirable Target for Future Therapies Against HIV-1. Curr. Top.
Microbiol. Immunol. 2015, 389, 53-92.
J. L., Mutations in the N-terminal domain of human
immunodeficiency virus type 1 nucleocapsid protein affect virion core
structure and proviral DNA synthesis. J. Virol. 1997, 71 (9), 6973-81.
2.
Hartman, T. L.; Yang, L.; Helfrick, A. N.; Hassink, M.;
18.
Stoylov, S. P.; Vuilleumier, C.; Stoylova, E.; De
Shank, N. I.; George Rosenker, K.; Scerba, M. T.; Saha, M.; Hughes,
E.; Wang, A. Q.; Xu, X.; Gupta, P.; Buckheit, R. W., Jr.; Appella, D.
H., Preclinical evaluation of a mercaptobenzamide and its prodrug for
NCp7-targeted inhibition of human immunodeficiency virus.
Antiviral Res. 2016, 134, 216-225.
Rocquigny, H.; Roques, B. P.; Gerard, D.; Mely, Y., Ordered
aggregation of ribonucleic acids by the human immunodeficiency
virus type 1 nucleocapsid protein. Biopolymers 1997, 41 (3), 301-12.
19.
Mori, M.; Dietrich, U.; Manetti, F.; Botta, M., Molecular
dynamics and DFT study on HIV-1 nucleocapsid protein-7 in
complex with viral genome. J. Chem. Inf. Model. 2010, 50 (4), 638-
50.
3.
Gamba, E.; Mori, M.; Kovalenko, L.; Giannini, A.; Sosic,
A.; Saladini, F.; Fabris, D.; Mely, Y.; Gatto, B.; Botta, M.,
Identification of novel 2-benzoxazolinone derivatives with specific
inhibitory activity against the HIV-1 nucleocapsid protein. Eur. J.
Med. Chem. 2018, 145, 154-164.
20.
Tisne, C.; Roques, B. P.; Dardel, F., Specific recognition of
primer tRNA Lys 3 by HIV-1 nucleocapsid protein: involvement of
the zinc fingers and the N-terminal basic extension. Biochimie 2003,
85 (5), 557-61.
4.
Mori, M.; Kovalenko, L.; Malancona, S.; Saladini, F.; De
Forni, D.; Pires, M.; Humbert, N.; Real, E.; Botzanowski, T.;
Cianferani, S.; Giannini, A.; Dasso Lang, M. C.; Cugia, G.; Poddesu,
B.; Lori, F.; Zazzi, M.; Harper, S.; Summa, V.; Mely, Y.; Botta, M.,
Structure-Based Identification of HIV-1 Nucleocapsid Protein
Inhibitors Active against Wild-Type and Drug-Resistant HIV-1
Strains. ACS Chem. Biol. 2018, 13 (1), 253-266.
21.
McCauley, M. J.; Rouzina, I.; Manthei, K. A.; Gorelick, R.
J.; Musier-Forsyth, K.; Williams, M. C., Targeted binding of
nucleocapsid protein transforms the folding landscape of HIV-1 TAR
RNA. Proc. Natl. Acad. Sci. U. S. A. 2015, 112 (44), 13555-60.
22.
Goudreau, N.; Hucke, O.; Faucher, A. M.; Grand-Maitre,
C.; Lepage, O.; Bonneau, P. R.; Mason, S. W.; Titolo, S., Discovery
and structural characterization of a new inhibitor series of HIV-1
nucleocapsid function: NMR solution structure determination of a
ternary complex involving a 2:1 inhibitor/NC stoichiometry. J. Mol.
Biol. 2013, 425 (11), 1982-98.
5.
Breuer, S.; Chang, M. W.; Yuan, J.; Torbett, B. E.,
Identification of HIV-1 inhibitors targeting the nucleocapsid protein.
J. Med. Chem. 2012, 55 (11), 4968-77.
6.
Sosic, A.; Sinigaglia, L.; Cappellini, M.; Carli, I.; Parolin,
C.; Zagotto, G.; Sabatino, G.; Rovero, P.; Fabris, D.; Gatto, B.,
Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Lysyl-
Peptidyl-Anthraquinone Conjugates. Bioconjug. Chem. 2016, 27 (1),
247-56.
23.
Saladini, F.; Giannini, A.; Boccuto, A.; Vicenti, I.; Zazzi,
M., Agreement between an in-house replication competent and a
reference replication defective recombinant virus assay for measuring
phenotypic resistance to HIV-1 protease, reverse transcriptase, and
integrase inhibitors. J. Clin. Lab. Anal. 2017, 32 (1).
7.
Sosic, A.; Cappellini, M.; Scalabrin, M.; Gatto, B.,
Nucleocapsid Annealing-Mediated Electrophoresis (NAME) assay
allows the rapid identification of HIV-1 nucleocapsid inhibitors. J.
Vis. Exp. 2015, (95), 52474.
24.
Darlix, J. L.; de Rocquigny, H.; Mely, Y., The multiple
roles of the nucleocapsid in retroviral RNA conversion into proviral
DNA by reverse transcriptase. Biochem. Soc. Trans. 2016, 44 (5),
1427-1440.
8.
Mori, M.; Nucci, A.; Lang, M. C.; Humbert, N.; Boudier,
C.; Debaene, F.; Sanglier-Cianferani, S.; Catala, M.; Schult-Dietrich,
P.; Dietrich, U.; Tisne, C.; Mely, Y.; Botta, M., Functional and
Structural Characterization of 2-Amino-4-phenylthiazole Inhibitors of
the HIV-1 Nucleocapsid Protein with Antiviral Activity. ACS Chem.
Biol. 2014, 9 (9), 1950-5.
25.
Darlix, J. L.; de Rocquigny, H.; Mauffret, O.; Mely, Y.,
Retrospective on the all-in-one retroviral nucleocapsid protein. Virus
Res. 2014, 193, 2-15.
26.
Bernacchi, S.; Mely, Y., Exciton interaction in molecular
beacons: a sensitive sensor for short range modifications of the
nucleic acid structure. Nucleic Acids Res. 2001, 29 (13), E62-2.
9.
Mori, M.; Schult-Dietrich, P.; Szafarowicz, B.; Humbert,
N.; Debaene, F.; Sanglier-Cianferani, S.; Dietrich, U.; Mely, Y.;
Botta, M., Use of virtual screening for discovering antiretroviral
compounds interacting with the HIV-1 nucleocapsid protein. Virus
Res. 2012, 169 (2), 377-87.
27.
Bernacchi, S.; Stoylov, S.; Piemont, E.; Ficheux, D.;
Roques, B. P.; Darlix, J. L.; Mely, Y., HIV-1 nucleocapsid protein
activates transient melting of least stable parts of the secondary
structure of TAR and its complementary sequence. J. Mol. Biol. 2002,
317 (3), 385-99.
10.
Mori, M.; Manetti, F.; Botta, M., Predicting the binding
mode of known NCp7 inhibitors to facilitate the design of novel
modulators. J. Chem. Inf. Model. 2011, 51 (2), 446-54.
28.
Miller, B. R.; McGee, T. D.; Swails, J. M.; Homeyer, N.;
Gohlke, H.; Roitberg, A. E., MMPBSA.py: An Efficient Program for
End-State Free Energy Calculations. J. Chem. Theory Comput. 2012,
8 (9), 3314-3321.
11.
Spriggs, S.; Garyu, L.; Connor, R.; Summers, M. F.,
Potential intra- and intermolecular interactions involving the unique-5'
region of the HIV-1 5'-UTR. Biochemistry 2008, 47 (49), 13064-73.
12.
Amarasinghe, G. K.; De Guzman, R. N.; Turner, R. B.;
Chancellor, K. J.; Wu, Z. R.; Summers, M. F., NMR structure of the
HIV-1 nucleocapsid protein bound to stem-loop SL2 of the psi-RNA
ACS Paragon Plus Environment